Abstract
Objective:To investigate the association of gold standard liver biomarkers with serum cytokeratin 18 (CK18), serum Alanine aminotransferase (ALT) and serum aspartate (AST).Methods:This was cross sectional study. It was conducted at Mayo Hospital from January 2016 to December 2017. It comprised of 148 non-alcoholic fatty liver disease subjects of age 40-60 years. After written informed consent, study anthropometric measurements (age, height, waist circumference and hip circumference) were taken and serum AST, ALT and CK-18 were estimated by sandwiched ELISA technique. Data was analyzed using SPSS 21.0. Descriptive were presented as mean and standard deviation. Association between CK18, serum AST and ALT were analyzed by regression analysis and are presented as beta coefficient. P-value ≤ 0.05 was taken as significant.Results:Study comprised of 148 subjects with mean age 44.81±6.2. Of total population 29.1% were male and 70.9% were female. Significant positive association of CK18 was found with serum ALT (P-value 0.005*). However, no association was found between AST and serum CK18. (P-value 0.29).Conclusion:Significant positive association was found between Serum CK18 and serum ALT.
Highlights
Non-alcoholic fatty liver disease (NAFLD) is becoming prevalent due to progressive increase in prevalence of obesity and diabetes
NAFLD is one of the utmost common reasons of chronic liver diseases leading to complications like simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and eventually hepatocellular carcinoma (HCC) which is the foremost indication for liver transplantation.[2]
Raised levels of serum ALT and AST might be present in NAFLD patients, though levels within normal do not eliminate the existence of NAFLD and NASH.[7]
Summary
Non-alcoholic fatty liver disease (NAFLD) is becoming prevalent due to progressive increase in prevalence of obesity and diabetes. Liver biopsy is the gold standard for NAFLD diagnosis and to assess its progression. The relative complications and high expenses of gold standard test utilized for the diagnosis of NAFLD has insisted the field to pursuit for more diagnostic methods.[4] Evidence based researches have suggested that serum biomarkers including serum AST, ALT and CK18 have a remarkable role in early detection of the liver diseases.[5] Elevation of serum transaminase levels in NAFLD patients has been well documented by previous studies. Aim of the study was to find the association of liver biomarkers serum AST and ALT with CK18 which can be used as diagnostic biomarker as well as marker for disease progression in future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
